GlaxoSmithKline, $1.04 billion
U.S. ex rel. Graydon v. GlaxoSmithKline,
District of Massachusetts.
Firm attorneys served as lead counsel for whistleblowers alleging that GlaxoSmithKline (GSK) engaged in illegal promotion of the company’s popular asthma and Chronic Obstructive Pulmonary Disease (COPD) medication, Advair. The case culminated in a $1.04 billion recovery for the federal and state governments.